Vanderbilt University Medical Center
Hematology and Oncology fellowship · Nashville, TN · Program website
This program's roster hasn't been collected yet, so there's no list of its own faculty and papers. Below is Vanderbilt University Medical Center's research in hematology and oncology, which the program shares with other departments and affiliated hospitals.
About Vanderbilt University Medical Centerinstitution-wide hematology and oncology research
Hematology and Oncology publications from Vanderbilt University Medical Center and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
362
works per year
12th of 74 hematology and oncology fellowship programs
-0.8%
2-year growth
60th of 74 hematology and oncology fellowship programs
33.5%
in top 10% of field (works before 2025)
5th of 72 hematology and oncology fellowship programs
53.2%
cited above world average
3rd of 72 hematology and oncology fellowship programs
Works per year · * 2026 so far
Oncology · 1,121Hematology · 634
Hematology and Oncology research topics at Vanderbilt University Medical Center
Papers in the window; each links to the list on OpenAlex.
- Cancer Immunotherapy and Biomarkers 241
- Acute Myeloid Leukemia Research 225
- Hematopoietic Stem Cell Transplantation 211
- CAR-T cell therapy research 157
- Colorectal Cancer Treatments and Studies 76
- Multiple Myeloma Research and Treatments 66
- Pancreatic and Hepatic Oncology Research 55
- COVID-19 and healthcare impacts 53
Most cited at Vanderbilt University Medical Center since 2024
All hematology and oncology papers there on OpenAlex
- The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023Lisa M Force et al. · The Lancet · 2025 · PubMed · cited 498
- Colorectal cancerCathy Eng et al. · The Lancet · 2024 · PubMed · cited 480
- Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in OncologyAl B. Benson et al. · Journal of the National Comprehensive Cancer Network · 2024 · PubMed · cited 406
- Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trialSandra P. D’Angelo et al. · The Lancet · 2024 · PubMed · cited 319
- NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024Al B. Benson et al. · Journal of the National Comprehensive Cancer Network · 2024 · PubMed · cited 312
- Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In OncologyJaffer A. Ajani et al. · Journal of the National Comprehensive Cancer Network · 2025 · PubMed · cited 243
- Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trialNizar M. Tannir et al. · Annals of Oncology · 2024 · PubMed · cited 236
- Management of Locally Advanced Rectal Cancer: ASCO GuidelineAaron James Scott et al. · Journal of Clinical Oncology · 2024 · PubMed · cited 204
- Global, regional, and national burden of breast cancer among females, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023Kayleigh Pavitra Bhangdia et al. · The Lancet Oncology · 2026 · PubMed · cited 174
- Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal CancerElena Élez et al. · New England Journal of Medicine · 2025 · PubMed · cited 174